



J. Lamarck Biotech - Class C

LU1053929581

UCITS IV SICAV

June 2026

selectra.tmf-group.com

www.lamarcksicav.eu

Investment strategy

The main objective of this sub-fund is to profit from increasing share prices in the biotechnology sector.

The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like Nasdaq or NYSE. The followed investment policy will enable the Sub-Fund to increase overall return relative to the Nasdaq Biotech Index by active stock selection of companies, offering the most promising technology platform.

Cumulative fund performance

	Fund
YTD	0.78%
1 month	-7.72%
3 months	-1.38%
6 months	0.78%
1 year	31.02%
From Inception *	69.14%

Drawdown analysis

Depth	Length	Recovery	Peak	Valley
-40.84%	26	-	Aug-21	Oct-23
-41.94%	32	-	Aug-21	Apr-24
-48.19%	43	-	Aug-21	Mar-25

Top 5 holdings

Asset	Market Value (EUR)	% AUM
Denali Therapeutics Inc Reg	7,897,577	9.9
Ionis Pharmaceuticals Inc	7,630,041	9.5
Intellia Therapeutics Inc	4,971,351	6.2
Biogen Inc	4,725,308	5.9
Exelixis Inc	3,807,891	4.7

Fund data


NAV class C (30.06.2026)	EUR 419.58
AUM	EUR 78.94 Mio
Launch date	June 20 th , 2014
Domiciliation	2, rue d'Alsace, L-1122 Luxembourg
R.C.S.	Luxembourg, B136880
Investment Manager	J. Lamarck Asset Management S.A.
Auditor	Deloitte Audit S.à r.l.
Depository Bank	Quintet Private Bank (Europe) S.A.
Contact	TMF Fund Management S.A. 46A, Avenue John F. Kennedy L-1855 Luxembourg Tel: +352 42 71 71 1

info.fundmanagement@tmf-group.com

Fund performance



Industry sector allocation



Investment terms

	Class A	Class B	Class C	Class D
Advisory Fee	up to 1.30% p.a	up to 2.50% p.a	up to 2.50% p.a	up to 2.50% p.a
Minimum amount invested	EUR 1,000,000	EUR 5,000	EUR 5,000	1 share
Performance fee	20% p.a with HWM**	20% p.a with HWM**	20% p.a with HWM**	20% p.a with HWM**
Bloomberg ticker	SELJLBT LX	SELJLBB LX	SELJBC LX	SELJLB IM
ISIN	LU0574993464	LU0574994512	LU1053929581	LU1246176264

* Inception Date: June 20th, 2014

** High Water Mark

For more details regarding the investment in this Fund, including potential risks, please refer to the current Full or Simplified Prospectus (the "Prospectus") available at SIS's offices.

This Fund is a sub-fund of the Luxembourg-registered Selectra Investments SICAV ("SIS"). This document has been prepared solely for information purposes and shall not be considered as an advice or solicitation to invest in SIS. Shares in SIS will only be issued and distributed on the basis of the Prospectus. The strategy employed may result in the Net Asset Value of the Fund exhibiting a high level of volatility and SIS is only suitable for investors in a position to take such risks. The value of investments may go down as well up and you may not get back your original investment. Changes in rate of exchange between currencies may cause the value of investments to decrease or increase. No liability whatsoever is accepted by SIS for any loss howsoever arising from any use of this report or its contents.